MedicineNet.com
About Us | Privacy Policy | Site Map
November 23, 2009
MedicineNet home Picture Slideshows Diseases and conditions Symptoms and signs Procedures and tests Medications Health and Living Picture Image Collection MedTerms medical dictionary
Font Size
A
A
A

Hepatitis C (cont.)

What is the role of a liver biopsy in the management of chronic hepatitis C?

Blood tests can tell the clinician whether HCV is present but cannot tell the level of liver damage that has occurred. Liver biopsy allows the clinician to determine how much inflammation and scarring is present in a small sample of liver tissue. Liver biopsy may be recommended when the clinician is uncertain about whether to begin treatment or wishes to monitor the response within the liver to therapy.

Who should receive antiviral therapy for hepatitis C virus?

Patients at risk for cirrhosis should be considered for treatment of HCV. According to a consensus statement from the National Institutes of Health (NIH) these include persons with:

  • HCV infection and persistent elevation of ALT (alanine aminotransferase, a liver enzyme in the blood)

  • High levels of HCV RNA in the blood

  • HCV infection and evidence of fibrosis (scarring) on liver biopsy

  • HCV infection and evidence of at least moderate inflammation and liver cell injury (necrosis) on liver biopsy

These are general guidelines. Patients and providers may decide that treatment is needed for other reasons. For example, patients with HIV have a more rapid course of liver injury and may need treatment at an earlier stage. Newer therapies may be offered to selected patients in research settings.

Individuals who should not be treated with antiviral therapy include those who are unable to comply with the treatment schedule, should not take the specific medications (for example, allergy), and have reversible serious untreated conditions such as unstable heart disease, uncontrolled high blood pressure, or untreated major depression.

Patients with unstable (decompensated) cirrhosis are at high risk for complications for treatment and usually do not receive medical treatment, except in research settings. Fundamentally, the decision regarding antiviral therapy in chronic HCV infection should be tailored to the individual patient with careful consideration of the risks and benefits.

All patients with HCV should be vaccinated against hepatitis B and hepatitis A. They also should be counseled on measures to prevent the spread of HCV and eliminating alcohol use. Finally, risk behaviors for HCV overlap with those of HIV, and all patients with HCV should be tested for HIV.

What are the different patterns of response to antiviral treatment?

Treatment responses are mainly defined by results of the HCV RNA testing. Four patterns of response to antiviral treatment have been described:

  1. sustained virologic response,

  2. relapse,

  3. partial response, and

  4. non-response.

Sustained virologic response

The optimal response is a sustained virologic response (SVR), defined as the absence of detectable HCV RNA in serum using a sensitive test at the end of the treatment and six months later. Most of these individuals will remain in remission (no signs of the disease) indefinitely, with no detectable hepatitis C virus RNA in the blood or liver. Moreover, follow-up biopsies show a marked reduction in inflammation and there even can be regression of scarring. Longer follow-up of these patients is necessary, however, to evaluate definitively whether sustained responders will avoid the complications of cirrhosis and live longer.

Relapse

Relapsers are patients who initially eliminate the RNA from their blood but then develop detectable RNA again shortly after discontinuing therapy. The RNA becomes detectable again within six months and usually within the first three months of stopping treatment.

Partial responders

Patients whose HCV RNA levels decline but never become undetectable are referred to as partial responders.

No response

Patients who have sustained levels of detectable HCV RNA during therapy are known as non-responders. Patients in whom HCV RNA becomes undetectable during the early period of treatment but reappears before the end of therapy, should probably likewise be considered non-responders. This reappearance of HCV RNA during therapy is referred to as a 'break through' of HCV.



Next: What are the goals of therapy for hepatitis C virus? »

Hepatitis C - How Was Diagnosis Established

The MedicineNet physician editors ask:

What was or has been the treatment for your hepatitis C, and was it effective?

Comment submissions for this question have ended. Patient Discussions FAQs
See 20 Viewer Comments

View Comments


Printer-Friendly Format  |  Email to a Friend


Suggested Reading by Our Doctors
MedicineNet Doctors
  • interferon - Describes the medication interferon (Roferon-A, Intron-A, Rebetron, Alferon-N, Peg-Intron, Avonex, Betaseron, Infergen, Actimmune, Pegasys), a drug used in managing many diseases that involve the immune system.
  • Liver Blood Tests - Learn about liver blood tests used to detect liver damage disease such as fatty liver, cirrhosis, hepatitis, Tylenol liver damage, and more. This includes measuring the aminotransferases enzymes (AST and ALT levels)
  • Diabetes - Learn about type 1 and 2 diabetes (Diabetes Mellitus) symptoms including increased urination, thirst, weight loss, fatigue, nausea, vomiting, skin infections, and blurred vision. Causes and diagnosis information is provided in the information.

Latest Medical News


Women's Health

Find out what women really need.


Are you Depressed? Take the Quiz

Your Guide to Symptoms & Signs: Pinpoint Your Pain












Health categories:

Slideshows | Diseases & Conditions | Symptoms & Signs | Procedures & Tests | Medications | Health & Living | News & Views | Medical Dictionary

Popular health centers:

Allergies | Arthritis | Cancer | Diabetes | Digestion | Healthy Kids | Heart | Men's Health | Mental Health | Women's Health | More...

Publications:

ePublications (PDFs) | XML News via RSS | Audio Podcasts | Email Newsletters

MedicineNet.com:

About Us | Privacy Policy | Site Map | WebMD® | Medscape® | eMedicine® | eMedicineHealth® | RxList®

This website is certified by Health On the Net Foundation. Click to verify. This site complies to the HONcode standard for trustworthy health information:
verify here.

©1996-2009 MedicineNet, Inc. All rights reserved. Notices and Legal Disclaimer.
MedicineNet does not provide medical advice, diagnosis or treatment. See additional information.